See the published version of this preprint at BMC Medical Genetics.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research article
Chao Liang
The First Affiliated Hospital of Nanjing Medical University
Corresponding Author
ORCiD: https://orcid.org/0000-0002-4716-8009
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background Published studies present conflicting data regarding the impact of Thrombospondin-1 (TSP-1) expression on prognosis of various cancers. We performed this meta-analysis to illustrate the preliminary predictive value of TSP-1.
Methods Twenty-four studies with a total of 2379 patients were included. A comprehensive literature search was performed by using PubMed, Cochrane Library, Web of Science, Embase, and hand searches were also conducted of relevant bibliographies. Pooled hazard ratios (HRs) with 95% confidence intervals (CIs) for patient survival and disease recurrence were initially identified to explore relationships between TSP-1 expression and patient prognosis.
Results A total of 24 eligible studies were included in this meta-analysis. Our results showed that high level of TSP-1 was correlated significantly with poor overall survival (OS) (HR=1.40, 95% CI: 1.17~1.68; P＜0.001). However, high TSP-1 expression predicted no significant impact on progression-free survival (PFS)/ metastasis-free survival (MFS) (HR=1.35, 95%CI: 0.87-2.10; P=0.176) and disease-free survival (DFS)/ recurrence-free survival (RFS) (HR = 1.40, 95%CI: 0.77–2.53; P=0.271). In addition, we performed subgroup analyses which showed that high TSP-1 expression predicted poor prognosis in breast cancer and gynecological cancer. Additionally, the relatively small number of studies on PFS/MFS and DFS/RFS is a limitation. The data extracted through Kaplan-Meier curves may not be accurate. Moreover, only English articles were included in this article, which may lead to deviations in the results.
Conclusions Our findings indicated high TSP-1 expression may act as a promising biomarker of poor prognosis in cancers, especially in breast cancer and gynecological cancer.
Keywords
TSP-1, Malignant neoplasm, Prognosis, Overall survival, Meta-analysis
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
This is a list of supplementary files associated with this preprint. Click to download.
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at BMC Medical Genetics.
Version 3
Posted 19 Jun, 2020
No community comments so far
Submission checks complete
On 18 Jun, 2020
Editorial decision: Accept
On 18 Jun, 2020
No comments provided
Editorial decision: Minor revision
On 05 Jun, 2020
Review #1 received
Received 04 Jun, 2020
Reviewer #2 agreed
On 03 Jun, 2020
Review #2 received
Received 03 Jun, 2020
Reviewers invited
Invitations sent on 02 Jun, 2020
Reviewer #1 agreed
On 02 Jun, 2020
Editor assigned
On 01 Jun, 2020
Submission checks complete
On 31 May, 2020
Editor invited
On 31 May, 2020
No comments provided
Review #2 received
Received 18 May, 2020
Editorial decision: Minor revision
On 18 May, 2020
Reviewer #2 agreed
On 30 Apr, 2020
Review #1 received
Received 26 Apr, 2020
Reviewer #1 agreed
On 11 Apr, 2020
Reviewers invited
Invitations sent on 06 Apr, 2020
Editor assigned
On 17 Mar, 2020
Submission checks complete
On 16 Mar, 2020
Editor invited
On 16 Mar, 2020
First submitted
On 13 Mar, 2020
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Medical Genetics
Learn more about our company.
See the published version of this preprint at BMC Medical Genetics.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research article
Chao Liang
The First Affiliated Hospital of Nanjing Medical University
Corresponding Author
ORCiD: https://orcid.org/0000-0002-4716-8009
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at BMC Medical Genetics.
Version 3
Posted 19 Jun, 2020
No community comments so far
Submission checks complete
On 18 Jun, 2020
Editorial decision: Accept
On 18 Jun, 2020
No comments provided
Editorial decision: Minor revision
On 05 Jun, 2020
Review #1 received
Received 04 Jun, 2020
Reviewer #2 agreed
On 03 Jun, 2020
Review #2 received
Received 03 Jun, 2020
Reviewers invited
Invitations sent on 02 Jun, 2020
Reviewer #1 agreed
On 02 Jun, 2020
Editor assigned
On 01 Jun, 2020
Submission checks complete
On 31 May, 2020
Editor invited
On 31 May, 2020
No comments provided
Review #2 received
Received 18 May, 2020
Editorial decision: Minor revision
On 18 May, 2020
Reviewer #2 agreed
On 30 Apr, 2020
Review #1 received
Received 26 Apr, 2020
Reviewer #1 agreed
On 11 Apr, 2020
Reviewers invited
Invitations sent on 06 Apr, 2020
Editor assigned
On 17 Mar, 2020
Submission checks complete
On 16 Mar, 2020
Editor invited
On 16 Mar, 2020
First submitted
On 13 Mar, 2020
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Medical Genetics
License:
This work is licensed under a CC BY 4.0 License. Read Full License
View the published article at BMC Medical Genetics.
Background Published studies present conflicting data regarding the impact of Thrombospondin-1 (TSP-1) expression on prognosis of various cancers. We performed this meta-analysis to illustrate the preliminary predictive value of TSP-1.
Methods Twenty-four studies with a total of 2379 patients were included. A comprehensive literature search was performed by using PubMed, Cochrane Library, Web of Science, Embase, and hand searches were also conducted of relevant bibliographies. Pooled hazard ratios (HRs) with 95% confidence intervals (CIs) for patient survival and disease recurrence were initially identified to explore relationships between TSP-1 expression and patient prognosis.
Results A total of 24 eligible studies were included in this meta-analysis. Our results showed that high level of TSP-1 was correlated significantly with poor overall survival (OS) (HR=1.40, 95% CI: 1.17~1.68; P＜0.001). However, high TSP-1 expression predicted no significant impact on progression-free survival (PFS)/ metastasis-free survival (MFS) (HR=1.35, 95%CI: 0.87-2.10; P=0.176) and disease-free survival (DFS)/ recurrence-free survival (RFS) (HR = 1.40, 95%CI: 0.77–2.53; P=0.271). In addition, we performed subgroup analyses which showed that high TSP-1 expression predicted poor prognosis in breast cancer and gynecological cancer. Additionally, the relatively small number of studies on PFS/MFS and DFS/RFS is a limitation. The data extracted through Kaplan-Meier curves may not be accurate. Moreover, only English articles were included in this article, which may lead to deviations in the results.
Conclusions Our findings indicated high TSP-1 expression may act as a promising biomarker of poor prognosis in cancers, especially in breast cancer and gynecological cancer.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Loading...